Results 231 to 240 of about 44,183 (305)

Systematic Metabolic Engineering and Model‐Guided Optimization for High‐Level Production of L‐Theanine From Xylose in Escherichia Coli

open access: yesAdvanced Science, EarlyView.
This study is pioneering in constructing the shortest known synthetic pathway for L‐theanine production from xylose within E coli. Through comprehensive metabolic engineering strategies, our engineered strain achieved the highest reported L‐theanine titer from xylose, with a titer of 95.42 g/L, and a yield of 0.55 g/g.
Haolin Han   +5 more
wiley   +1 more source

A Prussian Blue Nanozyme‐Adjuvanted Vaccine Presenting Phosphocholine Antigens for Induction of Immunotolerance in Inflammatory Bowel Disease

open access: yesAdvanced Science, EarlyView.
ABSTRACT Inflammatory bowel disease (IBD) is a complex disorder characterized by chronic intestinal inflammation and impaired barrier function, for which effective long‐term therapies remain elusive. To address this challenge, we developed a novel nano‐vaccine that combines Prussian blue nanozymes (PBNZs) adjuvants with a ferritin carrier loaded with ...
Jingyi Sheng   +6 more
wiley   +1 more source

Combining Electrochemical Reduction with Biosynthesis for Directed Conversion of CO2 into a Library of C3 Chemicals

open access: yesAdvanced Science, EarlyView.
In the H‐type electrolytic cell, carbon dioxide is reduced to acetic acid via electro‐microbial catalysis. The simply processed acetic acid is further converted through biological fermentation into high‐value‐added products, including acrylic acid, L‐lactic acid, and β‐alanine.
Kaixing Xiao   +8 more
wiley   +1 more source

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Calreticulin (CALR) mutations are prevalent in 20%–30% of patients with BCR::ABL1‐negative myeloproliferative neoplasms (MPN). Mutant calreticulin (mutCALR), presented by the thrombopoietin receptor (MPL, also known as TPOR or CD110) on the surface of the disease‐initiating MPN progenitors, represents an ideal target for curative ...
Shengen Xiong   +5 more
wiley   +1 more source

Non‐RASopathy Genetic Syndromes Identified as the Molecular Cause of Disease in Patients Previously Diagnosed With Noonan Syndrome

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Noonan Syndrome (NS) is a clinically and genetically heterogeneous condition characterized by typical facial dysmorphisms, short stature, congenital heart defects, and developmental delays. While variants in genes such as PTPN11, SOS1, and RAF1 account for most genetically confirmed cases, diagnosis is challenging due to phenotypic overlap ...
Gabriela Jeesoo Kim   +9 more
wiley   +1 more source

A comprehensive update of genotype-phenotype correlations in PMM2-CDG: insights from molecular and structural analyses. [PDF]

open access: yesOrphanet J Rare Dis
Oliveira T   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy